687 Proteomic profiling in blood identifies novel pretreatment and mechanistic markers related to inflammatory adverse events in relapsed/refractory large B-cell lymphoma after axicabtagene ciloleucel
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.